Show simple item record

AuthorEljilany, Islam
AuthorElarref, Mohamed
AuthorShallik, Nabil
AuthorElzouki, Abdel-Naser
AuthorMohammed, AbdulMoqeeth
AuthorShoman, Bassam
AuthorIbrahim, Sami
AuthorCarr, Cornelia
AuthorAl-Badriyeh, Daoud
AuthorCavallari, Larisa H.
AuthorElewa, Hazem
Available date2021-09-30T21:07:19Z
Publication Date2021-06
Identifierhttp://dx.doi.org/10.1016/j.cpcardiol.2021.100816
URIhttp://hdl.handle.net/10576/23594
AbstractBackground: The use of anticoagulant bridging remains controversial. This study was conducted to evaluate our warfarin periprocedural management in Qatar and investigate the associated clinical outcomes with such management. Methods: A prospective cohort study was designed to describe the periprocedural clinical practice in warfarin patients in Qatar and to compare clinical safety and efficacy outcomes between anticoagulant bridging and nonbridging. Results: 103 patients were recruited. Bridging occurred in 82% of the participants. No thromboembolic events were observed, while 39.1% of patients experienced bleeding events during the study period. The incidence of overall bleeding and major bleeding were numerically higher for bridging group compared to nonbridging but did not reach statistical significance ([30.6% vs 22.2%, P = 0.478] and [12.9% vs 5.6%, P = 0.375], respectively). Conclusion: Warfarin interruption and bridging are overwhelmingly used in warfarin-treated patients in Qatar. While bridging was numerically associated with increased bleeding events, there is no statistical difference in reported clinical events between bridging and nonbridging strategies.
Languageen
PublisherElsevier
SubjectPatients
Periprocedural Anticoagulation
TitlePeriprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study
TypeArticle
Issue Number6
Volume Number46
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record